Avicanna Inc. (TSX:AVCN)

Avicanna Inc. (TSX:AVCN) is driving biopharmaceutical advancements of plant-derived cannabinoid-based products. Founded in 2016, this Canadian-based company focuses on advancing and commercializing evidence-based cannabinoid products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform, including R&D and clinical development, with a commercialized portfolio of 30+ products. The company's offerings encompass medical cannabis and wellness products (RHO Phyto™), which are widely available in Canada and expanding into international markets. Additionally, leveraging its scientific platform, Avicanna has an extensive pipeline of indication-specific, patent-pending drug candidates aimed at addressing unmet medical needs in dermatology, chronic pain, and various neurological disorders. Notably, Avicanna's first pharmaceutical preparation, Trunerox™, is approved in Colombia and undergoing registration in other South American markets. Furthermore, Avicanna operates MyMedi.ca Medical Cannabis Care, a platform designed to better serve medical cannabis patients' needs and enhance their journey. This platform provides a diverse portfolio of products, pharmacist-led patient support programs, and specialty services for distinct patient groups. It also collaborates with public and private providers for adjudication and reimbursement while offering educational resources to facilitate the incorporation of medical cannabis into health care regimens. The company recently secured a $888.13K post-IPO equity investment on 04 December 2023. Avicanna's strategic focus on evidence-based cannabinoid products, along with its diverse product offerings and international expansion, positions it as an impactful player in the biotechnology and pharmaceutical industries.